

# Paula De Melo Campos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10915850/publications.pdf>

Version: 2024-02-01

18  
papers

173  
citations

1307594

7  
h-index

1199594

12  
g-index

18  
all docs

18  
docs citations

18  
times ranked

375  
citing authors

#	ARTICLE	IF	CITATIONS
1	Accelerated low-density neutrophil transition in sickle cell anaemia may contribute to disease pathophysiology. <i>British Journal of Haematology</i> , 2022, 197, 232-235.	2.5	5
2	NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. <i>Investigational New Drugs</i> , 2021, 39, 736-746.	2.6	7
3	Platelet counts on peripheral blood and Mean Platelet Volume as markers of clinical severity in Sickle Cell Disease. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 91, 102592.	1.4	0
4	Crizanlizumab Therapy Is Associated with Lower Levels of Circulating Extracellular Vesicles in Sickle Cell Disease Patients. <i>Blood</i> , 2021, 138, 955-955.	1.4	0
5	Platelet Counts and Mean Platelet Volume As Markers of Clinical Severity in Sickle Cell Disease. <i>Blood</i> , 2020, 136, 36-37.	1.4	0
6	Mutations in Triple-Negative Patients with Myeloproliferative Neoplasms. <i>Blood</i> , 2019, 134, 5395-5395.	1.4	2
7	The U2AF homology motif kinase 1 (UHMK1) is upregulated upon hematopoietic cell differentiation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 959-966.	3.8	8
8	Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. <i>Diagnostic Pathology</i> , 2016, 11, 28.	2.0	16
9	Pharmacological IRS1/2 Inhibition Induces Apoptosis in BCR-ABL1T315I mutant Cells. <i>Blood</i> , 2016, 128, 1886-1886.	1.4	0
10	ANKHD1 silencing inhibits Stathmin 1 activity, cell proliferation and migration of leukemia cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 583-593.	4.1	23
11	Differential profile of PIP4K2A expression in hematological malignancies. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 55, 228-235.	1.4	6
12	Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells. <i>Oncotarget</i> , 2015, 6, 29573-29584.	1.8	16
13	<i>YAP1</i> expression in myelodysplastic syndromes and acute leukemias. <i>Leukemia and Lymphoma</i> , 2014, 55, 2413-2415.	1.3	11
14	Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. <i>Leukemia Research</i> , 2014, 38, 251-257.	0.8	28
15	Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. <i>Leukemia Research</i> , 2014, 38, 1245-1251.	0.8	47
16	ANKHD1 Interacts with the Proapoptotic Protein SIVA and Plays a Role in the Proliferation and Stathmin Activation of Acute Leukemia Cells.. <i>Blood</i> , 2012, 120, 2419-2419.	1.4	0
17	MDR-1 and GST Polymorphisms Are Involved in Myelodysplasia Progression,. <i>Blood</i> , 2011, 118, 3507-3507.	1.4	0
18	Reduced expression of FLIPSHORT in bone marrow of low risk myelodysplastic syndrome. <i>Leukemia Research</i> , 2007, 31, 853-857.	0.8	4